Published in Clin Cancer Res on February 01, 2002
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23
History of the Baylor Charles A. Sammons Cancer Center. Proc (Bayl Univ Med Cent) (2003) 2.15
Retracted Novel management of oral cancer: a paradigm of predictive oncology. Clin Med Res (2004) 2.14
Colorectal carcinogenesis: Review of human and experimental animal studies. J Carcinog (2009) 2.06
Clinical implications and utility of field cancerization. Cancer Cell Int (2007) 1.91
What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer (2010) 1.86
Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila) (2011) 1.62
Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol (2012) 1.57
Randomized phase II trial of lyophilized strawberries in patients with dysplastic precancerous lesions of the esophagus. Cancer Prev Res (Phila) (2011) 1.53
Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) (2011) 1.38
Molecular targets for cancer chemoprevention. Nat Rev Drug Discov (2009) 1.38
The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res (2014) 1.32
A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila) (2012) 1.21
Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol (2010) 1.20
Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila) (2011) 1.14
Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res (2009) 1.11
Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci (2015) 1.09
Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr Cancer (2011) 1.07
Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation. Gut (2005) 1.03
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat (2011) 1.01
Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev (2012) 0.98
Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer. PPAR Res (2012) 0.97
Green tea catechin intervention of reactive oxygen species-mediated ERK pathway activation and chronically induced breast cell carcinogenesis. Carcinogenesis (2011) 0.95
Ductal lavage is an inefficient method of biomarker measurement in high-risk women. Cancer Prev Res (Phila) (2009) 0.95
Epigenetic alterations in ultraviolet radiation-induced skin carcinogenesis: interaction of bioactive dietary components on epigenetic targets. Photochem Photobiol (2011) 0.95
Chemopreventive potential of natural compounds in head and neck cancer. Nutr Cancer (2010) 0.95
Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin Exp Metastasis (2005) 0.94
Grape seed proanthocyanidin suppression of breast cell carcinogenesis induced by chronic exposure to combined 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene. Mol Carcinog (2010) 0.94
Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer (2010) 0.93
A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev Res (Phila) (2009) 0.92
Mitochondrial DNA as a potential tool for early cancer detection. Hum Genomics (2006) 0.90
Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002. Clin Cancer Res (2002) 0.90
Mitochondria and cancer: past, present, and future. Biomed Res Int (2013) 0.90
Screening for cancer with molecular markers: progress comes with potential problems. Nat Rev Cancer (2012) 0.88
Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis. Neoplasia (2005) 0.88
Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines. PLoS One (2007) 0.87
Taurocholic acid metabolism by gut microbes and colon cancer. Gut Microbes (2016) 0.87
Early detection in head and neck cancer - current state and future perspectives. GMS Curr Top Otorhinolaryngol Head Neck Surg (2010) 0.86
Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung. Cancer Prev Res (Phila) (2010) 0.83
Classifying the precancers: a metadata approach. BMC Med Inform Decis Mak (2003) 0.82
Altered histology provides a positive clinical signal in the bronchial epithelium. Cancer Prev Res (Phila) (2011) 0.81
Results from a dose-response study using 3,3'-diindolylmethane in the K14-HPV16 transgenic mouse model: cervical histology. Cancer Prev Res (Phila) (2011) 0.81
Chemoprevention of lung cancer. Proc Am Thorac Soc (2009) 0.81
Automated sputum cytometry for detection of intraepithelial neoplasias in the lung. Anal Cell Pathol (Amst) (2012) 0.81
The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics. Acta Pharm Sin B (2015) 0.80
The association between telomere length and cancer risk in population studies. Sci Rep (2016) 0.80
Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review). Int J Oncol (2010) 0.78
Attacking breast cancer at the preinvasion stage by targeting autophagy. Womens Health (Lond Engl) (2013) 0.78
NSAIDs: Old Drugs Reveal New Anticancer Targets. Pharmaceuticals (Basel) (2010) 0.78
How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective. Eur J Nucl Med Mol Imaging (2014) 0.77
Increasing incidence of colon cancer in patients <50 years old: a new entity? Ann Transl Med (2016) 0.77
Disorders related with ageing in the gerbil female prostate (Skene's paraurethral glands). Int J Exp Pathol (2009) 0.77
We can really reduce the risk for prostate cancer? World J Urol (2003) 0.76
Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer. J Clin Trials (2014) 0.76
Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions. Cancer Prev Res (Phila) (2013) 0.76
Insulin, insulin-like growth factor 1 and insulin-like growth factor binding protein 3 serum concentrations in patients with adenomatous colon polyps. Prz Gastroenterol (2013) 0.75
Multiple therapeutic and preventive effects of 3,3'-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia. J Biomed Res (2014) 0.75
Non-enzymatic, serum-free tissue culture of pre-invasive breast lesions for spontaneous generation of mammospheres. J Vis Exp (2014) 0.75
Oral Administration of Fermented Soymilk Products Protects the Skin of Hairless Mice against Ultraviolet Damage. Nutrients (2016) 0.75
Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Onco Targets Ther (2016) 0.75
Phase II cancer prevention clinical trials. Semin Oncol (2010) 0.75
High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction. World J Urol (2003) 0.75
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
Lung cancer. N Engl J Med (2008) 13.49
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
Knockout rats via embryo microinjection of zinc-finger nucleases. Science (2009) 12.33
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Lung cancer in never smokers--a different disease. Nat Rev Cancer (2007) 6.41
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med (1991) 6.39
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Esophageal carcinoma. N Engl J Med (2014) 5.77
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res (2007) 5.32
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst (2005) 5.22
Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst (2003) 5.09
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology (2005) 4.71
Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer (2004) 4.70
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med (2013) 4.64
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol (2004) 4.48
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA (2004) 4.31
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
A risk model for prediction of lung cancer. J Natl Cancer Inst (2007) 4.25
Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res (2003) 4.22
Reactive oxygen species: a breath of life or death? Clin Cancer Res (2007) 4.20
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Statins and cancer prevention. Nat Rev Cancer (2005) 4.12
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Pancreatic cancer: novel approaches to diagnosis and therapy. Gastroenterology (2005) 4.06
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer (2007) 4.01
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer (2006) 3.92
Genomic alterations in cultured human embryonic stem cells. Nat Genet (2005) 3.89
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell (2006) 3.73
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol (2013) 3.65
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61
Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther (2007) 3.61
Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development (2005) 3.57
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res (2006) 3.45
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Focus on lung cancer. Cancer Cell (2002) 3.41
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res (2006) 3.40
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer (2007) 3.35